

Tecan to present at UBS Global Life Sciences Conference

Männedorf, Switzerland, September 17, 2012 – The Tecan Group (SIX Swiss Exchange: TECN) today announced that it will present at the UBS Global Life Sciences Conference on September 20, 2012 in New York City.

The investor presentation by Gérard Vaillant, acting CEO and member of the Board of Directors of Tecan, will begin at 08:30 a.m. EDT (14:30 p.m. CET) and will be webcast live. The webcast may be accessed under the "Investor Relations" tab of Tecan's website www.tecan.com.

A replay of the webcast will be available shortly following the presentation and will remain available for four weeks.

About Tecan

Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the life sciences sector. Its clients include pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments and components that are then distributed by partner companies. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both Europe and North America and maintains a sales and service network in 52 countries. In 2011, Tecan generated sales of CHF 377 million (USD 424 million; EUR 306 million). Registered shares of Tecan Group are traded on the SIX Swiss Exchange (TK: TECN/Reuters: TECZn.S/ ISIN: 1210019).

For further information:

Tecan Group

Martin Braendle Head of Corporate Communications & Investor Relations Tel. +41 (0) 44 922 84 30 Fax +41 (0) 44 922 88 89 <u>investor@tecan.com</u> www.tecan.com